PMID- 22200084
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20171116
IS  - 2210-7762 (Print)
VI  - 204
IP  - 11
DP  - 2011 Nov
TI  - FISH-based determination of HER2 status in circulating tumor cells isolated with 
      the microfluidic CEE platform.
PG  - 589-95
LID - 10.1016/j.cancergen.2011.10.011 [doi]
AB  - Determination of HER2 status in breast cancer patients is considered standard 
      practice for therapy selection. However, tumor biopsy in patients with recurrent 
      and/or metastatic disease is not always feasible. Thus, circulating tumor cells 
      (CTCs) are an alternative source of tumor cells for analysis of HER2. An antibody 
      cocktail for recovery of variable, high- and low-, EpCAM-expressing tumor cells 
      was developed based on FACS evaluation and then verified by CTC enumeration 
      (based on CK and CD45 staining) with comparison to EpCAM-only and with 
      CellSearch(R) (n=19). HER2 fluorescence in situ hybridization (FISH) on all (CK+ 
      and CK-) captured cells was compared to HER2 status on the primary tumors (n=54) 
      of patients with late stage metastatic/recurrent breast cancer. Capture of low 
      EpCAM-expressing tumor cells increased from 27% to 76% when using the cocktail 
      versus EpCAM alone, respectively. Overall, CTC detection with the OncoCEE 
      platform was better compared to CellSearch(R) (68% vs. 89%, respectively), and a 
      93% concordance in HER2 status was observed. HER2 FISH analysis of CK+ and CK- 
      CTCs is feasible using the CEE platform. Although larger clinical studies are 
      warranted, the results demonstrate adequate sensitivity and specificity as needed 
      for incorporation into laboratory testing.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Mayer, Julie Ann
AU  - Mayer JA
AD  - Biocept Inc., San Diego, CA, USA.
FAU - Pham, Tam
AU  - Pham T
FAU - Wong, Karina L
AU  - Wong KL
FAU - Scoggin, Jayne
AU  - Scoggin J
FAU - Sales, Edgar V
AU  - Sales EV
FAU - Clarin, Trisky
AU  - Clarin T
FAU - Pircher, Tony J
AU  - Pircher TJ
FAU - Mikolajczyk, Stephen D
AU  - Mikolajczyk SD
FAU - Cotter, Philip D
AU  - Cotter PD
FAU - Bischoff, Farideh Z
AU  - Bischoff FZ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
RN  - EC 3.1.3.48 (PTPRC protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*pathology
MH  - Cell Separation/*methods
MH  - Creatine Kinase/blood
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Leukocyte Common Antigens/blood
MH  - Microfluidic Analytical Techniques/*methods
MH  - Middle Aged
MH  - Neoplastic Cells, Circulating/*chemistry
MH  - Receptor, ErbB-2/*blood
EDAT- 2011/12/28 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/12/28 06:00
PHST- 2011/08/09 00:00 [received]
PHST- 2011/10/21 00:00 [revised]
PHST- 2011/10/24 00:00 [accepted]
PHST- 2011/12/28 06:00 [entrez]
PHST- 2011/12/28 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - S2210-7762(11)00304-8 [pii]
AID - 10.1016/j.cancergen.2011.10.011 [doi]
PST - ppublish
SO  - Cancer Genet. 2011 Nov;204(11):589-95. doi: 10.1016/j.cancergen.2011.10.011.